Patent application number | Description | Published |
20090042214 | BETA2-MICROGLOBULIN AND C REACTIVE PROTEIN (CRP) AS BIOMARKERS FOR PERIPHERAL ARTERY DISEASE - The present invention relates to use of β-2-microglobulin (B2M or β2M) and C-reactive protein (CRP) levels as biomarkers of peripheral artery disease and/or atherosclerosis. | 02-12-2009 |
20100113353 | Method and composition for inhibiting cardiovascular cell proliferation - Cardiovascular cell proliferation in a blood vessel subjected to trauma, such as angioplasty, vascular graft, anastomosis, or organ transplant, can be inhibited by contacting the vessel with a polymer consisting of from 6 to about 30 amino acid subunits, where at least 50% of the subunits are arginine, and the polymer contains at least six contiguous arginine subunits. Exemplary polymers for this purpose include arginine homopolymers 7 to 15 subunits in length. | 05-06-2010 |
20110313681 | BIOMARKERS FOR PERIPHERAL ARTERY DISEASE - This invention provides biomarkers whose concentrations in blood plasma are associated with the presence or absence of PAD in the patient from whom the plasma sample is taken. The invention also provides biomarkers for distinguishing between PAD patients who are long claudicators and PAD patients who are not. In addition, the invention provides methods for identifying additional biomarkers, methods for detecting the biomarkers in patients, and methods for identifying agents, including pharmaceutical agents, which interact with the biomarkers and are useful for preventing or treating PAD in patients. | 12-22-2011 |
20120208232 | Cell-Free Synthesis of Active Reprogramming Transcription Factors - Compositions and methods are provided for the cell-free synthesis of active reprogramming factor polypeptides. The reprogramming factors may be synthesized as fusion proteins comprising a permeant domain, such as polyarginme. The cell free-synthesis may be conducted at about 25 C in a bacterial cell extract from genetically alterd cells having decreased endogenous protease activity Further, the proteins may comprise a fusion partner which enhances solubility and may be refolded on a column. | 08-16-2012 |
20130202649 | ACTIVATION OF INNATE IMMUNITY FOR NUCLEAR REPROGRAMMING OF SOMATIC CELLS - The nuclear reprogramming of somatic cells with non-integrating factors is shown to be greatly accelerated by activation of innate immune responses in the somatic cell. Methods of activating innate immunity include activation of toll-like receptors, e.g. TLR3. Somatic cells with activated innate immune responses can be reprogrammed to induced pluripotent cells or to transdifferentiated cells. | 08-08-2013 |
20130224259 | Dimethylarginine Dimethylaminohydrolase Inhibitors and Methods of Use Thereof - The present disclosure provides DDAH modulators. Thus, the present disclosure provides a method of treating a patient suffering from a disorder characterized by excessive NO production and/or elevated DDAH activity, the method comprising administering to said patient an effective amount of a compound of one of formulae I-X. The present disclosure also provides a pharmaceutical composition comprising a compound of one of formulae I-X. | 08-29-2013 |
20130260389 | BETA-2 MICROGLOBULIN AS A BIOMARKER FOR PERIPHERAL ARTERY DISEASE - The present invention provides β2 microglobulin as a biomarker for qualifying or assessing peripheral artery disease in a subject. | 10-03-2013 |
20140187519 | BIOMARKERS FOR PREDICTING MAJOR ADVERSE EVENTS - Provided herein are diagnostic markers and uses thereof for predicting if a subject is at risk of a major adverse event. In particular, one aspect provided herein relates to methods to determine if a subject is at risk of having a major adverse effect by measuring at least 2, or at least 3 of the biomarkers beta 2 microglobulin, c-reactive protein and cystatin C. | 07-03-2014 |
20140242347 | Graft For Directed Vascular And Lymphatic Regeneration And Methods To Guide Endothelial Cell Assembly - Embodiments of the present invention relate to a therapeutic device (graft) comprising a collagen membrane having an aligned uniaxial or biaxial structure such that mammalian cells plated on the membrane align mainly along the direction of the collagen fibrils. In a further aspect, a graft comprising a substantially tubular body, wherein the body has an exterior surface, an interior surface, and at least one lumen extending therethrough such that a fluid flow through the lumen can direct mammalian cell migration. In a further aspect, mammalian cells or growth and angiogenic factors can be optionally attached to the exterior and/or interior surface of the substantially tubular body. In various aspects, the graft can be used as a vascular prosthesis, a stent, or a nerve regeneration scaffold. Methods of preparing and implanting same are also provided. | 08-28-2014 |